The incidence of chronic pain is on the rise, and around 1 in 5 Europeans suffer from a chronic pain condition. Current pharmacological treatment options include a vast array of drugs but despite the availability of so many treatment options, both acute and chronic pain may go unresolved.

Opti-Ease has been developed by IMCD experts to target several processes involved in pain and inflammation and is based on compelling scientific evidence.